Valeo’s
Canadian Roots
Rooted in specialty pharma, Valeo is devoted to (growing) Canadian healthcare by licencing and acquiring Canadian rights to commercial stage, innovative and proprietary drugs (with no development or clinical activities associated risks.).
Listed on the CSE Feb’19 and has secured
$37M+ Funding
Founded in 2003, Valeo Pharma originally focused on dermatology and Hospital specialty, until 2014 when it sold its entire product portfolio to Valeant ($27M).
Management and a growing base of employees (100+) is now refocused on large new therapeutic areas and commercializing drugs in Canada.
Since the sale, Including Bought Deal in June 2021
$11.5M
Since the sale, Including
Bought Deal in June 2021
$11.5M
Listed on the CSE Feb’19
and has secured
$37M+ Funding
Areas of Focus
Valeo’s company growth is coming by way of four therapeutic areas, showcased at right.
Respiratory
Specialty Products
Neurology
Oncology
Within these four areas we now have 8 marketed brands and 4 additional products contributing to 100% growth in our 2021 revenues.
4
Therapeutic areas
8
Market Brands
4
Additional Products
This focused growth plan is already resulting in pivotal growth in 2021:
100%
Growth Estimated
Valeo’s Fully Integrated
Capabilities
Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization
